AI For Pharma Growth

Enterprise AI is shifting from experiments to infrastructure, and that changes everything. In this episode, Dr Andree Bates interviews Jocelyn Houle, Senior Director of Product Management at Securiti.ai, to explore the future of enterprise AI, agents, automation, and the single biggest blocker to scale: trust.

Jocelyn shares what she is seeing across highly regulated industries as organisations move beyond proof of concept into production. She explains why the agent era raises the stakes: when you add LLMs into workflows, systems become non-deterministic and harder to trace end to end. In her words, once the data goes in, you cannot easily untangle it, so organisations need stronger controls around permissions, auditing, and policy enforcement.

A major theme is that data foundations matter more than ever. Jocelyn warns that agents will not magically repair messy data, they will expose weak data quality immediately. From there, she outlines how trust can be won or lost at the prompt layer, both outbound (what the model says to customers) and inbound (what users share with the organisation). She also discusses “toxic combinations”, where overlapping access can accidentally leak sensitive information, plus the growing need for prompt screening and tracking to reduce risk.
The conversation also digs into explainability and auditability, with Jocelyn being refreshingly honest that the perfect solution is not here yet. Instead, enterprises are using practical approaches like benchmarking releases side by side, cataloguing AI agents in use, and building governance that is starting to look more like modern cybersecurity: baked in from the start, not added as an afterthought.
Jocelyn closes with clear advice for leaders: start “left” with raw data controls, build a truly cross-functional team, and begin setting up auditability even with imperfect tools, because regulators are catching up and they will expect responsible behaviour.

Topics Covered
Where enterprise AI adoption really stands today

What makes AI agents different from traditional automation

Non-determinism, traceability, and why permissions matter

Data mapping, policy controls, and reducing sensitive data leakage

Prompt security: outbound and inbound trust risks

“Toxic combinations” and exposure through agent workflows

Explainability, benchmarking, and parallel release testing

AI governance becoming as essential as cybersecurity

Top 3 pieces of advice for CTOs starting their AI journey

Why enterprise AI will become so embedded we stop talking about it

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.

This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

Dr. Andree Bates LinkedIn | Facebook | X

About the Podcast

Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr Andree Bates is joined by Dr Joseph Geraci of NetraMark to break down why trials fail so often, how patient heterogeneity drives cost and uncertainty, and where AI can realistically shift the economics.
Joseph shares his unusual path from mathematics and mathematical physics into oncology and medical science, including a decision to move into hospital research rather than follow a more traditional academic route. That shift shaped his focus: not just discovering more molecules, but understanding why the same drug can work brilliantly for some patients and fail for others.
A central theme is that clinical trials are not “one disease, one patient type”. In many areas, disease definitions are too broad for trial design, making trials feel like trying to hit multiple dartboards with one dart. Joseph explains how NetraMark’s approach aims to identify meaningful subpopulations inside small datasets, finding the “pocket” where a drug’s true advantage shows up, without discarding patients as outliers.
The conversation also touches on regulators, including growing interest in innovation pathways, but also the fear pharma teams have about changing protocols and risking setbacks. Joseph argues that AI’s biggest economic value in trials is speed, using better insight from limited trial data to guide enrichment strategies, smarter substudy decisions, and faster iteration, especially in oncology and rare disease where time is everything.

Topics Covered
Why clinical trial economics are becoming unsustainable

Patient heterogeneity and why disease definitions break trials

Finding “pockets” of responders within small datasets

Trial enrichment and substudies that reveal a drug’s advantage

Why pharma adoption can be slow, even when failures are constant

Regulatory interest, guidelines, and sponsor risk aversion

Large language models vs mathematically augmented AI approaches

Speed as the biggest economic lever in trials

Practical examples across depression, schizophrenia, oncology, and beyond

What clinical trials could look like in five years with AI-driven insight

This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more. 

Dr. Andree Bates LinkedIn | Facebook | X

AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.

Dr Andree explains the core paradox: AI can now synthesise literature at speed, accelerate discovery, and outperform human experts in specific tasks, but the business results are often disappointing because the failure is rarely technical. It is strategic. She describes the “technical obsession trap”, where organisations spend months optimising models and benchmarking competitors while adoption remains low and teams are not operationally ready to act on the outputs.

She outlines three common failure modes:
Innovation Theatre, where disconnected pilots never compound into enterprise value

Competitor benchmarking, where companies copy use cases that do not fit their context

Technology first strategy, where tools are bought before priorities are defined

From there, she maps what a strong pharma AI blueprint must cover: grounding in business objectives, end to end deployment architecture (data, governance, capability, change), leadership and culture, rigorous financial modelling tied to revenue and ROI, and alignment across functions including commercial, medical, regulatory, R&D, market access, insights, and tech teams.

Dr Andree closes with a clear challenge for leadership: competitive advantage will come to organisations that build the most intelligent operating model around AI, not those with the biggest budgets. She also offers a 45 minute AI strategic diagnostic for pharma and biotech leaders who want an honest read on what to fix before investing further.

Topics Covered
Why pharma AI impact often disappoints despite powerful tools

The “technical obsession trap” and the AI strategy blind spot

Innovation Theatre, competitor benchmarking, and technology first mistakes

What a pharma AI strategic blueprint must include

Governance as a foundation for scale and regulatory trust

Leadership, culture, and adoption as the real differentiators

Financial modelling and prioritisation based on ROI and revenue impact

Organisational alignment across the full pharma value chain

Choosing the right advisory partner and avoiding generic frameworks

Why strategy must come before technology to build durable advantage

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.

This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

Dr. Andree Bates LinkedIn | Facebook | X

Healthcare accessibility is still being held hostage by phone queues, missed calls, and clunky portals. In this episode, Dr Andree Bates sits down with Josh Taylor of TxtSquad to explore why simple, secure texting can remove friction for patients and providers, and how AI can support the conversation without making care feel robotic.
Josh explains why SMS works where apps often fail: it is familiar, low effort, and asynchronous. That means patients can reply on their own time, while care teams can manage conversations in a way that fits real clinic workflows instead of forcing everyone into yet another platform.
They dig into the pharma and adherence angle too. Josh shares how two-way messaging helps teams move beyond generic reminders and uncover the real reasons people stop taking medication, opening the door to earlier support, smarter interventions, and better outcomes.
Finally, Josh outlines where AI adds value inside messaging: triage for common questions, translation, summarisation, and staff copilots. He also highlights the importance of compliance, clear boundaries, and human oversight when dealing with sensitive health information. The future, he suggests, is smarter communication across SMS, voice, and phone-based assistants, designed to meet patients where they already are.

Topics Covered
Why portals and apps struggle with adoption in healthcare

SMS as a low-barrier, asynchronous engagement channel

Building a two-way patient to provider communication loop

Medication adherence: understanding drop-off, not just sending reminders

Patient assistance programmes and support at scale

Clinical trial recruitment and retention using messaging

AI in messaging: triage, translation, summarisation, and staff copilots

Compliance considerations and handling sensitive information

What comes next: voice agents and deeper integration with phone workflows

About the Podcast
AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.
This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.
AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.
As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.
This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business
Dr. Andree Bates LinkedIn | Facebook | X

As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews Dr Morteza Zihayat of Heisenberg Network to explore Human-Centred AI: designing intelligent systems that prioritise welfare, autonomy, dignity and trust over pure technical capability.

Morteza explains how his background in data mining led to a key insight: numbers can be incredibly powerful, but they still “miss the mark” when human values are ignored. That perspective shaped his work in Human-Centred AI and helped inspire Heisenberg Network, a decentralised infrastructure designed to transform fragmented, messy data into high-quality, AI-ready intelligence — in minutes rather than weeks — while dramatically reducing cost.

The conversation digs into what human-centred design looks like in practice. Morteza introduces a “ladder of priorities” to manage conflicting values — from safety and laws at the top, through ethics and platform policies, down to individual preferences — and argues that making this ladder public gives people a right to debate and appeal decisions when something feels wrong.

Finally, Morteza tackles the unavoidable trade-offs between performance and fairness, sharing a real example from mental health research where reducing model accuracy produced a fairer system that clinicians felt more comfortable using. His key message is urgent: powerful AI is coming either way — making it human-centred is a choice we need to commit to now, with transparency becoming non-negotiable.
Topics Covered
What Human-Centred AI means in practice

Turning user stories into concrete design checks

The “ladder of priorities” for managing conflicting values

Designing systems for welfare, autonomy, dignity and trust

Power caps and keeping AI controllable

Personalisation vs wellbeing (and avoiding filter bubbles)

Where bias enters: data, models, and feedback loops

Debiasing pipelines and fairness as real-world data shifts

Learning from users without storing raw personal data

Explainability challenges with reasoning models

Why transparency is becoming non-negotiable

When less accuracy can be the more responsible choice

About the Podcast
AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.
This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.

As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.

This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business.

Dr. Andree Bates LinkedIn | Facebook | X